Download Animal Models in Cancer Drug Discovery Ebook PDF

Animal Models in Cancer Drug Discovery

Animal Models in Cancer Drug Discovery
A Book

by Asfar Azmi,Ramzi M. Mohammad

  • Publisher : Academic Press
  • Release : 2019-04-16
  • Pages : 470
  • ISBN : 0128147059
  • Language : En, Es, Fr & De
GET BOOK

Animal Models in Cancer Drug Discovery brings forward the most cutting-edge developments in tumor model systems for translational cancer research. The reader can find under this one volume virtually all types of existing and emerging tumor models in use by the research community. This book provides a deeper insight on how these newer models could de-risk modern drug discovery. Areas covered include up to date information on latest organoid derived models and newer genetic models. Additionally, the book discusses humanized animal tumor models for cancer immunotherapy and how they leverage personalized therapies. The chapter on larger animal, canine models and their use in and their use in pre-investigational new drug (pre-IND) development makes the volume unique. Unlike before, the incorporation of several simplified protocols, breeding methodologies, handling and assessment procedures to study drug intervention makes this book a must read. Animal Models in Cancer Drug Discovery is a valuable resource for basic and translational cancer researchers, drug discovery researchers, contract research organizations, and knowledge seekers at all levels in the biomedical field. Encompasses discussions on innovative animal models, xenograft, genetic models, primary models, organoid systems, humanized and other models in modern biology paradigms that are enhancing research in the field of drug discover Covers the use of these models in personalized medicine, immunotherapy, toxicology, pre-IND assessments and related drug development arenas Presents protocols, procedures, and a comprehensive glossary to help new readers understand technical terms and specialized nomenclature

Animal Models for Human Cancer

Animal Models for Human Cancer
Discovery and Development of Novel Therapeutics

by Marianne I. Martic-Kehl,Pius August Schubiger

  • Publisher : John Wiley & Sons
  • Release : 2016-05-18
  • Pages : 272
  • ISBN : 3527695893
  • Language : En, Es, Fr & De
GET BOOK

Based on results from the past ten years, this ready reference systematically describes how to prepare, carry out, and evaluate animal studies for cancer therapies, addressing the widely recognized lack of reliable and reproducible results. Following a short historical introduction and a discussion of the ethics surrounding animal experiments, the book describes correct study design as well as the handling and housing of animals. It then goes on to describe the animal models available for different cancer types, from natural cancer models in mice and dogs to humanized animals. An evaluation of previously unpublished long-term data from the Swiss canine and feline cancer registry is also included. The final part of the book reviews the lessons learned over the last decade on how to interpret data from animal studies for improving human therapy and gives recommendations for future drug development.

Molecular Cancer Therapeutics

Molecular Cancer Therapeutics
Strategies for Drug Discovery and Development

by George C. Prendergast

  • Publisher : John Wiley & Sons
  • Release : 2004-04-02
  • Pages : 368
  • ISBN : 9780471432029
  • Language : En, Es, Fr & De
GET BOOK

Molecular Cancer Therapeutics covers state-of-the-art strategies to identify and develop cancer drug target molecules and lead inhibitors for clinical testing. It provides a thorough treatment of drug target discovery, validation, and development. The introductory chapters provide an overview of pathways to discovery and development of molecular cancer therapeutics. Subsequent chapters progress from initial stages of drug target discovery to drug discovery, development, and testing in preclinical and clinical models. Topics include drug lead screening, drug-to-lead development, proof-of-concept studies, medicinal chemistry issues, intellectual property concerns, and clinical development. This invaluable reference promotes understanding of steps involved in developing drug leads for industrial partnering and development. It provides an overview of the strategies for discovery and validation of drug target molecules, and discusses cell- and molecule-based drug screening strategies, as well as mouse models for cancer. Coverage also includes how to refine drug leads for suitability in clinical testing, the special issues of clinical testing of molecular-targeted drugs, and intellectual property concerns.

Tumor Models in Cancer Research

Tumor Models in Cancer Research
A Book

by Beverly A. Teicher

  • Publisher : Humana Press
  • Release : 2010-12-02
  • Pages : 693
  • ISBN : 9781607619673
  • Language : En, Es, Fr & De
GET BOOK

The past 6 years since the first edition of this book have seen great progress in the development of genetically engineered mouse (GEM) models of cancer. These models are finding an important role in furthering our understanding of the biology of malignant disease. A comfortable position for GEM models in the routine conduct of screening for potential new therapeutics is coming more slowly but is coming. Increasing numbers of genetically engineered mice are available, some with conditional activation of oncogenes, some with multiple genetic changes providing mouse models that are moving closer to the human disease.

Molecular Diagnostics and Treatment of Pancreatic Cancer

Molecular Diagnostics and Treatment of Pancreatic Cancer
Systems and Network Biology Approaches

by Asfar Azmi

  • Publisher : Elsevier
  • Release : 2014-04-14
  • Pages : 458
  • ISBN : 0124079466
  • Language : En, Es, Fr & De
GET BOOK

Molecular Diagnostics and Treatment of Pancreatic Cancer describes the different emerging applications of systems biology and how it is shaping modern pancreatic cancer research. This book begins by introducing the current state of the art knowledge, trends in diagnostics, progress in disease model systems as well as new treatment and palliative care strategies in pancreatic cancer. Specific sections are dedicated to enlighten the readers to newer discoveries that have emerged from gene expression profiling, proteomics, metabolomics and systems level analyses of pancreatic cancer datasets. First of a kind and novel network strategies to understand oncogenic Kras signaling in pancreatic tumors are presented. The attempts to computationally model and prioritize microRNAs that cause pancreatic cancer resistance are also highlighted. Addressing this important area, Molecular Diagnostics and Treatment of Pancreatic Cancer provides insights into important network evaluation methodologies related to pancreatic cancer related microRNAs targetome. There are dedicated chapters on critical aspects of the evolving yet controversial field of pancreatic cancer stems cells. The work concludes by discussing the applications of network sciences in pancreatic cancer drug discovery and clinical trial design. Encompasses discussion of innovative tools including expression signatures in cell lines, 3D models, animal xenograft models, primary models and patient derived samples, aiding subversion of traditional biology paradigms, and enhancing comprehension across conventional length and temporal scales Coverage includes novel applications in targeted drugs, polypharmacology, network pharmacology and other related drug development arenas – helping researchers in pancreatic cancer drug discovery Summarizes many relevant computational and clinical references from fast-evolving literature Comprehensive glossary helps newer readers understand technical terms and specialized nomenclature

COX-2 Blockade in Cancer Prevention and Therapy

COX-2 Blockade in Cancer Prevention and Therapy
A Book

by Randall E. Harris

  • Publisher : Humana Press
  • Release : 2010-10-28
  • Pages : 371
  • ISBN : 9781617373046
  • Language : En, Es, Fr & De
GET BOOK

The revelation that aspirin and aspirin-like compounds have notableantineo plastic properties has revolutionized cancer research. COX-2 Blockade in Cancer Prevention and Therapy chronicles the evidence and presents exciting new op portunities for the use of cyclooxygenase-2 (COX-2) blockade in the prevention and treatment of cancer. The text is divided broadly into five areas. First, an historical overview documents the scientific discovery ofCOX-2 and the pharma ceutical development of nonsteroidal anti-inflammatory drugs (NSAIDs) designed for selective COX-2 inhibition. The process by which essential poly unsaturated fatty acids (PUF As) stimulate prostaglandin biosynthesis and cancer development, and its interruption by COX-2 inhibition, is elucidated. This is followed by a section on the epidemiology of NSAIDs and cancers of the colon and breast, and other anatomic sites. These chapters reflect significant cancer protection owing to the regular use of common NSAIDs such as aspirin and ibuprofen. A section on animal models of carcinogenesis presents comprehensive evidence that general NSAIDs inhibit a variety of malignant neoplasms in vivo, and highlights recent findings which show that COX-2 blocking agents produce striking chemopreventive effects against colon cancer and breast cancer as well as other malignancies. Genetic models are presented confirming the critical role of COX-2 in carcinogenesis. Section IV then discusses the molecular biology of COX -2 vis-a-vis the role of COX -2 and, to a lesser extent, COX -1, in modulating a number of important processes in molecular carcinogenesis such as mutagen esis, cell division, angiogenesis, cell differentiation, and apoptosis.

What Will We Do If We Don't Experiment on Animals?

What Will We Do If We Don't Experiment on Animals?
Medical Research for the Twenty-first Century

by Jean Swingle Greek,C. Ray Greek

  • Publisher : Trafford Publishing
  • Release : 2004
  • Pages : 261
  • ISBN : 1412020581
  • Language : En, Es, Fr & De
GET BOOK

Drs. Greek have written 2 books on why using animals as models for humans is not the best way to conduct medical research and drug testing. During their lectures and debates, the most commonly asked question was, "Well. What will we use if we don't use animals?" What Will We Do If We Don't Experiment On Animals? Medical Research for the Twenty-first Century is the answer to that question. Drs. Greek explain briefly why one species cannot predict drug response for another and describe what research and testing methods should be used today instead of animals. They also describe where our biomedical research dollars should be spent if we are to have cures for cancer, AIDS, and Alzheimer's. This book will appeal to science-trained and general audiences, animal lovers and science readers, public policy analysts, students, patients and patient support groups, and government watchdog groups. What Will We Do If We Don't Experiment On Animals? Medical Research for the Twenty-first Century takes medical research out of the nineteenth and into the 21st century.

Cytokines in the Genesis and Treatment of Cancer

Cytokines in the Genesis and Treatment of Cancer
A Book

by Michael A. Caligiuri,Michael T. Lotze

  • Publisher : Springer Science & Business Media
  • Release : 2007-09-19
  • Pages : 482
  • ISBN : 1597454559
  • Language : En, Es, Fr & De
GET BOOK

Cytokines in the Genesis and Treatment of Cancer provides a comprehensive picture of the dual role of host responses in promoting and inhibiting tumor progression. This volume represents an important investigation into the emerging intersection of cancer biology and cancer immunology. The book brings together an impressive array of internationally distinguished investigators who are devoted to the study of cytokines and cancer.

The Oncogenomics Handbook

The Oncogenomics Handbook
A Book

by William J. LaRochelle,Richard A. Shimkets

  • Publisher : Springer Science & Business Media
  • Release : 2007-11-09
  • Pages : 750
  • ISBN : 1592598935
  • Language : En, Es, Fr & De
GET BOOK

An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.

Basic Principles of Drug Discovery and Development

Basic Principles of Drug Discovery and Development
A Book

by Benjamin E. Blass

  • Publisher : Academic Press
  • Release : 2021-03-30
  • Pages : 712
  • ISBN : 0128172150
  • Language : En, Es, Fr & De
GET BOOK

Basic Principles of Drug Discovery and Development presents the multifaceted process of identifying a new drug in the modern era, which requires a multidisciplinary team approach with input from medicinal chemists, biologists, pharmacologists, drug metabolism experts, toxicologists, clinicians, and a host of experts from numerous additional fields. Enabling technologies such as high throughput screening, structure-based drug design, molecular modeling, pharmaceutical profiling, and translational medicine are critical to the successful development of marketable therapeutics. Given the wide range of disciplines and techniques that are required for cutting edge drug discovery and development, a scientist must master their own fields as well as have a fundamental understanding of their collaborator’s fields. This book bridges the knowledge gaps that invariably lead to communication issues in a new scientist’s early career, providing a fundamental understanding of the various techniques and disciplines required for the multifaceted endeavor of drug research and development. It provides students, new industrial scientists, and academics with a basic understanding of the drug discovery and development process. The fully updated text provides an excellent overview of the process and includes chapters on important drug targets by class, in vitro screening methods, medicinal chemistry strategies in drug design, principles of in vivo pharmacokinetics and pharmacodynamics, animal models of disease states, clinical trial basics, and selected business aspects of the drug discovery process. Provides a clear explanation of how the pharmaceutical industry works, as well as the complete drug discovery and development process, from obtaining a lead, to testing the bioactivity, to producing the drug, and protecting the intellectual property Includes a new chapter on the discovery and development of biologics (antibodies proteins, antibody/receptor complexes, antibody drug conjugates), a growing and important area of the pharmaceutical industry landscape Features a new section on formulations, including a discussion of IV formulations suitable for human clinical trials, as well as the application of nanotechnology and the use of transdermal patch technology for drug delivery Updated chapter with new case studies includes additional modern examples of drug discovery through high through-put screening, fragment-based drug design, and computational chemistry

Animal Models for Human Cancer, Volume 69

Animal Models for Human Cancer, Volume 69
Discovery and Development of Novel Therapeutics

by Marianne I. Martic-Kehl,Pius August Schubiger,Raimund Mannhold,Hugo Kubinyi,Gerd Folkers

  • Publisher : John Wiley & Sons
  • Release : 2016-08-15
  • Pages : 272
  • ISBN : 3527339973
  • Language : En, Es, Fr & De
GET BOOK

Based on results from the past ten years, this ready reference systematically describes how to prepare, carry out, and evaluate animal studies for cancer therapies, addressing the widely recognized lack of reliable and reproducible results. Following a short historical introduction and a discussion of the ethics surrounding animal experiments, the book describes correct study design as well as the handling and housing of animals. It then goes on to describe the animal models available for different cancer types, from natural cancer models in mice and dogs to humanized animals. An evaluation of previously unpublished long-term data from the Swiss canine and feline cancer registry is also included. The final part of the book reviews the lessons learned over the last decade on how to interpret data from animal studies for improving human therapy and gives recommendations for future drug development.

Translational Animal Models in Drug Discovery and Development

Translational Animal Models in Drug Discovery and Development
A Book

by Xinkang Wang

  • Publisher : Bentham Science Publishers
  • Release : 2012-10-03
  • Pages : 287
  • ISBN : 1608054691
  • Language : En, Es, Fr & De
GET BOOK

Animal models of diseases play a pivotal role in drug discovery and development, not only for proof of the concept studies of efficacy, PK/PD relationship but also for drug safety assessment. Since considerable differences in variables exist between animal models and human models (such as genetics, physiology, anatomy, gene expression, heterogeneity of disease conditions, etc.), not all the preclinical models are able to represent the pathophysiological conditions in human diseases. Therefore, partly due to the lack of congruency between animal and human disease models, several proposed therapeutic agents in the past decades have been demonstrated to be effective in preclinical models but failed in clinical studies. This e-book focuses on animal models of diseases from a translational perspective and highlights the key advantages and limitations of each model described to facilitate drug discovery and development. A unique feature of the volume is that it contains a selection of details disease models in various therapeutic niches with significant unmet medical needs, including inflammation, neurological diseases, cardiovascular and metabolic diseases, and oncology. This e-book is, therefore, of considerable value to researchers and clinicians involved in drug discovery and development as well as pathology.

Drug Discovery Toxicology

Drug Discovery Toxicology
From Target Assessment to Translational Biomarkers

by Yvonne Will,J. Eric McDuffie,Andrew J. Olaharski,Brandon D. Jeffy

  • Publisher : John Wiley & Sons
  • Release : 2016-03-22
  • Pages : 584
  • ISBN : 1119053390
  • Language : En, Es, Fr & De
GET BOOK

As a guide for pharmaceutical professionals to the issues and practices of drug discovery toxicology, this book integrates and reviews the strategy and application of tools and methods at each step of the drug discovery process. • Guides researchers as to what drug safety experiments are both practical and useful • Covers a variety of key topics – safety lead optimization, in vitro-in vivo translation, organ toxicology, ADME, animal models, biomarkers, and –omics tools • Describes what experiments are possible and useful and offers a view into the future, indicating key areas to watch for new predictive methods • Features contributions from firsthand industry experience, giving readers insight into the strategy and execution of predictive toxicology practices

Frontiers in Anti-Cancer Drug Discovery

Frontiers in Anti-Cancer Drug Discovery
A Book

by Atta-ur-Rahman,M. Iqbal Choudhary

  • Publisher : Bentham Science Publishers
  • Release : 2014-09-15
  • Pages : 413
  • ISBN : 1608059227
  • Language : En, Es, Fr & De
GET BOOK

Frontiers in Anti-Cancer Drug Discovery is an Ebook series devoted to publishing the latest and the most important advances in Anti-Cancer drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery, including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The Ebook series should prove to be of interest to all pharmaceutical scientists involved in research in Anti-Cancer drug design and discovery. Each volume is devoted to the major advances in Anti-Cancer drug design and discovery. The Ebook series is essential reading for all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Molecular Biology of Cancer: Translation to the Clinic

Molecular Biology of Cancer: Translation to the Clinic
A Book

by Anonim

  • Publisher : Academic Press
  • Release : 2010-12-16
  • Pages : 400
  • ISBN : 9780123850720
  • Language : En, Es, Fr & De
GET BOOK

Advances in molecular biology over the last several decades are being steadily applied to our understanding of the molecular biology of cancer, and these advances in knowledge are being translated into the clinical practice of oncology. This volume explores some of the most exciting recent advances in basic research on the molecular biology of cancer and how this knowledge is leading to advances in the diagnosis, treatment, and prevention of cancer. * This series provides a forum for discussion of new discoveries, approaches, and ideas * Contributions from leading scholars and industry experts * Reference guide for researchers involved in molecular biology and related fields

Cancer Chemoprevention

Cancer Chemoprevention
Volume 2: Strategies for Cancer Chemoprevention

by Gary J. Kelloff,Ernest T. Hawk,Caroline C. Sigman

  • Publisher : Springer Science & Business Media
  • Release : 2008-08-17
  • Pages : 543
  • ISBN : 1592597688
  • Language : En, Es, Fr & De
GET BOOK

Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development—those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can “reasonably predict” clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate endpoints for later-occurring drugs that take advantage of cellular control mechanisms clinical disease. Thus far, the biomarker that best measures to selectively suppress cancer progression. these two phenomena is intraepithelial neoplasia (IEN) Carcinogenesis is now visualized as a multifocal, because it is a near obligate precursor to cancer.

Cancer Drug Resistance

Cancer Drug Resistance
A Book

by Beverly A. Teicher

  • Publisher : Springer Science & Business Media
  • Release : 2007-11-09
  • Pages : 617
  • ISBN : 1597450359
  • Language : En, Es, Fr & De
GET BOOK

Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.

Biomaterials for 3D Tumor Modeling

Biomaterials for 3D Tumor Modeling
A Book

by Subhas C. Kundu,Rui L Reis

  • Publisher : Elsevier
  • Release : 2020-08-22
  • Pages : 772
  • ISBN : 012818129X
  • Language : En, Es, Fr & De
GET BOOK

Biomaterials for 3D Tumor Modeling reviews the fundamentals and most relevant areas of the latest advances of research of 3D cancer models, focusing on biomaterials science, tissue engineering, drug delivery and screening aspects. The book reviews advanced fundamental topics, including the causes of cancer, existing cancer models, angiogenesis and inflammation during cancer progression, and metastasis in 3D biomaterials. Then, the most relevant biomaterials are reviewed, including methods for engineering and fabrication of biomaterials. 3D models for key biological systems and types of cancer are also discussed, including lung, liver, oral, prostate, pancreatic, ovarian, bone and pediatric cancer. This book is suitable for those working in the disciplines of materials science, biochemistry, genetics, molecular biology, drug delivery and regenerative medicine. Reviews key biomaterials topics, including synthetic biomaterials, hydrogels, e-spun materials and nanoparticles Provides a comprehensive overview of 3D cancer models for key biological systems and cancer types Includes an overview of advanced fundamental concepts for an interdisciplinary audience in materials science, biochemistry, regenerative medicine and drug delivery

The First Cell

The First Cell
And the Human Costs of Pursuing Cancer to the Last

by Azra Raza

  • Publisher : Hachette UK
  • Release : 2019-10-15
  • Pages : 368
  • ISBN : 1541699505
  • Language : En, Es, Fr & De
GET BOOK

With the fascinating scholarship of The Emperor of All Maladies and the deeply personal experience of When Breath Becomes Air, a world-class oncologist examines the current state of cancer and its devastating impact on the individuals it affects -- including herself. In The First Cell, Azra Raza offers a searing account of how both medicine and our society (mis)treats cancer, how we can do better, and why we must. A lyrical journey from hope to despair and back again, The First Cell explores cancer from every angle: medical, scientific, cultural, and personal. Indeed, Raza describes how she bore the terrible burden of being her own husband's oncologist as he succumbed to leukemia. Like When Breath Becomes Air, The First Cell is no ordinary book of medicine, but a book of wisdom and grace by an author who has devoted her life to making the unbearable easier to bear.

Cancer Drug Design and Discovery

Cancer Drug Design and Discovery
A Book

by Stephen Neidle

  • Publisher : Elsevier
  • Release : 2011-04-28
  • Pages : 496
  • ISBN : 9780080554952
  • Language : En, Es, Fr & De
GET BOOK

The ultimate source of information on the design of new anticancer agents, emphasizing small molecules, this newest work covers recent notable successes resulting from the human genome and cancer genomics projects. These advances have provided information on targets involved in specific cancers that are leading to effective medicines for at least some of the common solid tumors. Unique sections explain the basic underlying principles of cancer drug development and provide a practical introduction to modern methods of drug design. Appealing to a broad audience, this is an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry and clinicians taking oncology options. * Covers both currently available drugs as well as those under development * Provides a clinical perspective on trials of new anticancer agents * Presents drug discovery examples through the use of case histories